EGFR突变肺癌一线治疗新思路,创新口服双靶药显独特优势( 二 )


参考文献:Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706). J Thorac Oncol;
本文为***作者原创 , 未经授权不得转载

推荐阅读